<DOC>
	<DOCNO>NCT00152191</DOCNO>
	<brief_summary>This randomize control study design evaluate relapse-free survival UFT group compare CMF group . Patients randomly assign receive either CMF UFT within 12 week curative resection . To evaluate treatment efficacy , data recurrence , survival collect 10 year enrollment final patient . To assess safety , data adverse event collect 2 year start treatment . Patients'quality life assess mean questionnaire .</brief_summary>
	<brief_title>A Randomized Controlled Study Postoperative Adjuvant Therapy Uracil-tegafur ( UFT ) Compared With Cyclophosphamide/Methotrexate/5-fluorouracil ( CMF ) Breast Cancer ( NSAS-BC )</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Methotrexate</mesh_term>
	<mesh_term>Fluorouracil</mesh_term>
	<mesh_term>Tegafur</mesh_term>
	<criteria>Age 18 75 Performance status 0 1 ( ECOG ) Hematopoietic WBC ≥ 4,000/mm^3 Platelet ≥ 100,000/mm^3 Hepatic AST ALT ≤ 2.5 time upper limit normal ( ULN ) Total bilirubin ≤ ULN Renal Creatinine ≤ ULN Prior anticancer treatment</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>July 2011</verification_date>
	<keyword>Breast Cancer</keyword>
</DOC>